FDA User Fee Review Staff Hiring To Be Lower Than Projected Under PDUFA III
Executive Summary
FDA plans to add 376 additional staff years to the drug review process over the course of PDUFA III, about 75 fewer than initial projections
You may also be interested in...
FDA PDUFA Performance Hampered By Inadequate Staffing – OND’s Jenkins
Staffing issues are affecting FDA performance goals as the agency enters the fourth iteration of the Prescription Drug User Fee Act
FDA PDUFA Performance Hampered By Inadequate Staffing – OND’s Jenkins
Staffing issues are affecting FDA performance goals as the agency enters the fourth iteration of the Prescription Drug User Fee Act
IND User Fees May Be Ready For “Prime Time” In PDUFA IV Negotiations
IND user fees are expected to be on the table during the next round of discussions over reauthorizing the Prescription Drug User Fee Act